After high-dose chemotherapy followed by HSCT, G-CSF or granulocyte-macrophage colony stimulating factor (GM-CSF) are used to minimize the rates of morbidity and mortality associated with prolonged neutropenia. Here, CSF2 is linked to Decreased total neutrophil count.